Clevidipine (the Medicines Company).
The Medicines Company (under license from AstraZeneca) is developing clevidipine, a short-acting dihydropyridine calcium antagonist, for the potential treatment of peri-operative hypertension. By 1997, the compound was undergoing phase II clinical evaluation by the original developer, AstraZeneca. By March 2002, The Medicines Company was conducting phase III clinical trials.
Zhang
Hongwei
H
Department of General Surgery, The Second Affiliated Hospital of Zhong Shan University, Guangzhou, PR China. hongweizhang67@hotmail.com
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D006801:Humans; D011725:Pyridines / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D011725:Pyridines; C118563:clevidipine